A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
Withdrawn
- Conditions
- Carcinoma
- Registration Number
- NCT00477425
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Signed Informed Consent Form
- Enrollment in one of a list of certain randomized, controlled bevacizumab trials
Exclusion Criteria
- Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
- Congenital long QT syndrome
- Family history of long QT syndrome
- Clinically significant bradycardia (defined as < 50 beats/minute)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method